Kyle W. Sloop
Eli Lilly (United States)(US)Oxford Centre for Diabetes, Endocrinology and Metabolism(GB)
Publications by Year
Research Areas
Diabetes Treatment and Management, Pancreatic function and diabetes, Receptor Mechanisms and Signaling, Neuropeptides and Animal Physiology, Metabolism, Diabetes, and Cancer
Most-Cited Works
- → LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept(2018)782 cited
- → Regulation of Expression of ob mRNA and Protein by Glucocorticoids and cAMP(1996)480 cited
- → Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist(2020)445 cited
- → How May GIP Enhance the Therapeutic Efficacy of GLP-1?(2020)375 cited
- → LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept(2022)254 cited
- → Hepatic and glucagon-like peptide-1–mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors(2004)214 cited